Sana Biotechnology, Inc. (SANA) announced Friday that the FDA has cleared its Investigational New Drug or IND application to initiate a study of SC262 in patients with relapsed or refractory B-cell malignancies, who have received prior CD19-directed CAR T therapy.
In the pre-market session, shares are at $4.89, up 7.14 percent from the previous close of $4.70.
SC262 expresses the same CAR, including the same CD22 binder, used in CD22-directed CAR T therapies tested in multiple academic clinical trials.
The company said, to date, these trials have shown durable complete responses in a substantial number of patients in the relapse setting following treatment with a CD19-directed CAR T therapy.
The company expects to present initial proof of concept data for SC262 later this year.
SC262 is a hypoimmune, CD22-directed allogeneic CAR T cell therapy derived from healthy donor CD4+ and CD8+ T cells.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.